Thursday, July 25, 2013
Publication and contact
Cell culture studies
suggest a noncompetitive, imidazoline-based proteasome inhibitor
could help treat cancer. In in vitro assays, the lead compound
inhibited the proteasome with an IC50 value of
130 nM without targeting the proteasome catalytic site. In cultured human
myeloma cell lines sensitive or insensitive to Velcade
the lead imidazoline-based inhibitor caused greater cell death than the
parent inhibitor. Next steps include evaluating the in vivo toxicity
of the lead inhibitor.
Pharmaceutical Co. Ltd. and Johnson
& Johnson market the competitive proteasome inhibitor
Velcade to treat multiple myeloma (MM) and mantle cell lymphoma.
Pharmaceuticals Inc. and Ono
Pharmaceutical Co. Ltd. market the selective proteasome
to treat MM.
At least 10 companies have proteasome inhibitors in Phase III testing or
earlier development to treat cancer.
Published online July 25, 2013
Patented; available for
licensing from Michigan
State University Technologies
Azevedo, L.M. et al. J.
Med. Chem.; published online June 22, 2013;
Contact: Jetze J. Tepe, Michigan State University, East
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]